



BIODIEM LTD  
ABN 20 096 845 993

Level 4,  
100, Albert Road,  
South Melbourne, Victoria, 3205  
Australia

Phone: +61 3 9692 7240  
Web: [www.biodiem.com](http://www.biodiem.com)

## LAIV Success in China

### Highlights

- Successful sales campaign in China following launch of Changchun BCHT Biotechnology Co. ("BCHT")'s "*Influenza Vaccine, Live, Nasal, Freeze-Dried*" last year.
- BCHT is BioDiem's licence holder for the BioDiem's LAIV technology for the private market in China
- BCHT listed successfully on the Shanghai STAR Exchange
- The royalty payment due to BioDiem is estimated to be more than US\$250,000 before taxes and deductions

**Melbourne, 30 June 2021:** Australian vaccine technology company BioDiem Ltd ("BioDiem") today announced the recent successes of its Chinese licensee, Changchun BCHT Biotechnology Co ("BCHT"). On 25 June 2021 BCHT listed on the Shanghai Stock Exchange Science and Technology Innovation Board, or STAR Market. This is a significant milestone in the history of the company which was established in 2004.

BCHT launched its LAIV influenza vaccine, "*Influenza Vaccine, Live, Nasal, Freeze-Dried*" in China in August 2020. At the close of this financial year the royalty payment due to BioDiem on sales of the product is estimated to be more than US\$250,000 before taxes and deductions.

Julie Phillips, CEO, BioDiem said, "We are delighted with the significant achievements of BCHT during the past year especially with difficulties due to COVID-19. The pandemic has increased awareness of the importance of vaccination in saving lives and the ease of administration of the LAIV vaccine, by a spray inside the nose, compared to the need for injections."

BioDiem's LAIV Vaccine business involves licensing its platform technology to vaccine manufacturers for the production of intranasal vaccines for the prevention of seasonal and pandemic influenza. BioDiem receives payment from licence fees and royalties on sales. BioDiem currently has two commercial partners: Serum Institute of India (Pune, India), and Changchun BCHT Biotechnology Co. (Jilin, China).

BioDiem's LAIV vaccine technology is also licensed to the World Health Organization (WHO) as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

- ENDS -

### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply.

Biodiem has two commercial licencees:

- Changchun BCHT Biotechnology Co (China) launched Defluvac™ in China in August 2020; and
- Serum Institute of India's Nasovac-S™ is marketed in India.

### **About Changchun BCHT Biotechnology Co,**

Invested by Changchun High-technology Industry Development Property (Group), BCHT was established in March 2004. This company is a high-tech enterprise engaged in research, development, production and marketing of biologics and drugs. BCHT now owns three manufacturing sites which cover 235,000 square meters in total and two R&D centers for Vaccine and drug with the most equipped laboratories and pilot plants in an area of more than 5,000 square meters. In the last few years, BCHT's R&D investment exceeds more than 400 million RMB.

In 2008, BCHT successfully launched its Varicella Vaccine, Live in China. In the following years, BCHT has continuously committed to improving the product and finally removed the gelatin from adjuvant and extended the vaccine shelf-life up to 36 months which is the longest in the world in 2011. These improvements not only enhanced the vaccine safety and quality but also established BCHT's leading position in varicella vaccine sector.

On 25 June 2021, BCHT formally became a listed company in science and technology innovation board in Shanghai Stock Exchange, which is another milestone in the history of BCHT.

For more information, please visit [www.bchtpharm.com](http://www.bchtpharm.com).

### **Further information**

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

Twitter @biodiem @opalbiosciences